DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options

Conditions: Chronic Hepatitis B

First Posted Date: 2002-08-01

Last Posted Date: 2014-01-07

Lead Sponsor: Gilead Sciences

Registration Number: NCT00042393

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery

Phase 1

Terminated

Conditions: Colorectal Neoplasms

First Posted Date: 2002-07-15

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT00041691

Locations: 🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States

Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Neoplasms

First Posted Date: 2002-07-15

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 75

Registration Number: NCT00041639

Locations: 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇳🇱
Academic Medical Center, Amsterdam, Netherlands

and more 7 locations

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer
Rectal Cancer
Colorectal Cancer
Colorectal Carcinoma
Breast Neoplasms
Colon Cancer
Colorectal Neoplasms

First Posted Date: 2002-07-15

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT00041652

Locations: 🇺🇸
Hoag Cancer Center, Newport Beach, California, United States

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Carcinoma
Colon Cancer
Rectal Cancer
Colorectal Neoplasms
Colorectal Cancer
Colorectal Tumor

First Posted Date: 2002-07-03

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 72

Registration Number: NCT00040599

Locations: 🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
Hoag Cancer Center, Newport Beach, California, United States
🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States

and more 7 locations

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir DF
Drug: Tenofovir alafenamide

First Posted Date: 2002-05-14

Last Posted Date: 2014-01-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT00036634

Locations: 🇺🇸
Rockefeller University Hospital, New York, New York, United States
🇺🇸
Protocare Trials Chicago Center for Clinical Trials, Chicago, Illinois, United States
🇺🇸
Stanford Positive Care Program, Palo Alto, California, United States

Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS

Not Applicable

Completed

Conditions: HIV Infections
Herpes Simplex

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Registration Number: NCT00002181

Locations: 🇺🇸
HIV Primary Care & Consult, Santa Rosa, California, United States
🇺🇸
AIDS Healthcare Foundation Labs, Los Angeles, California, United States
🇺🇸
Dr Susan M Diamond, Dallas, Texas, United States

and more 12 locations

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

Phase 1

Completed

Conditions: Herpes Simplex
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT00002116

Locations: 🇺🇸
Mount Zion Med Ctr / UCSF, San Francisco, California, United States
🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States

and more 6 locations

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 25

Registration Number: NCT00002234

Locations: 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
🇺🇸
Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

and more 2 locations

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2005-06-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 120

Registration Number: NCT00002184

Locations: 🇺🇸
Krauss Med Partners / Dept of Research and Development, Los Angeles, California, United States
🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇵🇷
Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy